查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1179526

神經生物標誌物市場：按類型（基因組,蛋白質組,代謝組,其他）,應用（阿爾茨海默病,多發性硬化症,帕金森病）2021-2031全球機會分析和行業預測

Neurological Biomarkers Market By Type (Genomic, Proteomic, Metabolomic, Others), By Application (Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease): Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 141 Pages | 商品交期: 2-3個工作天內

價格

神經生物標誌物是神經退行性疾□□病患者的生物學狀態或狀態的可測量指標。

腦部疾病需要許多標誌物來反映各種腦細胞的代謝紊亂。 最近引入的代謝組學分析方法可用於基於對與腦代謝相關的眾多生化成分的分析來研究神經系統疾病。

推動神經生物標誌物市場增長的主要因素有：易患神經系統疾病的老齡化人口增加、頭部損傷增加、阿爾茨海默病、帕金森病和多發性硬化症患病率上升等。 例如，根據世界衛生組織2020年發布的最新數據，澳大利亞帕金森病死亡人數達到2036人，佔所有死亡人數的1.49%。 澳大利亞的年齡調整死亡率為每10萬人3.35人，在世界上排名第131位。 根據世衛組織 2022 年更新報告，在全球範圍內，帕金森病致殘和死亡的增長速度超過任何其他神經系統疾病。

例如，根據國家多發性硬化症協會 2019 年的數據，美國 18 歲以上的人中有 75 萬到 100 萬患有多發性硬化症。 東北部和中西部的多發性硬化症患者多於南方。 自 1955 年以來，MS 的患病率在世界範圍內有所增加。 美國的第一份 MS 報告發表於 1976 年，發現 123,00 例。 1990 年的一項研究發現了 300,000 例 MS。 這與 2019 年估計的 75 萬至 100 萬患者相比是有利的。

此外，神經病學是個性化醫療作為阿爾茨海默病、帕金森病和多發性硬化症的治療方法而變得越來越重要的領域之一。 神經生物標誌物涵蓋個性化醫療的廣泛範圍，最終推動了對包含神經元生物標誌物的診斷的需求。 因此，對個性化醫療不斷增長的需求正在推動神經生物標誌物市場的增長。

此外，對微創手術日益增長的需求正在推動神經生物標誌物產品的採用。 此外，技術進步、各種產品發布、收購、合作夥伴關係、協議和其他主要戰略推動了神經生物標誌物市場的增長。 例如，2021 年 6 月，羅氏集團成員基因泰克及其母公司 Roche Holding AG 宣布，他們將能夠治療阿爾茨海默病、帕金森病、亨廷頓舞蹈病、肌萎縮側索硬化症 (ALS) 和自閉症 該公司宣布與加州大學舊金山分校 (UCSF) 和加州大學伯克利分校建立合作夥伴關係，以加速開發新療法，以治療衰弱性腦部疾病和中樞神經系統 (CNS) 疾病。 在十年的合作中，加州大學舊金山分校和加州大學伯克利分校從基因泰克公司獲得了高達 5300 萬美元的資金。

然而，有關阿爾茨海默病、帕金森病和多發性硬化症早期診斷的新出現的倫理問題預計會阻礙市場增長。 嚴格的政府法規和神經生物標誌物產品的高成本也抑制了市場增長。

此外，由於患者數量的增加，對阿爾茨海默病和帕金森病無創診斷技術的需求增加，藥物發現和開發的研發投入增加，以及神經病學意識的提高生物標誌物，對高級生物標誌物測試開發的日益關注預計將推動醫療保健業務的增長。 因此，預計在預測期內將為主要參與者提供有利可圖的市場投資機會。

神經生物標誌物市場根據類型、應用和區域進行細分。 按類型分為基因組學、蛋白質組學、代謝組學等。 按用途分為阿爾茨海默病、帕金森病和多發性硬化症。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特的五力分析
  • 主要公司的定位
  • 市場動態
    • 司機
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章神經生物標誌物市場：按類型

  • 概覽
    • 市場規模和預測
  • 基因組學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 蛋白質組學
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 代謝組
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章神經生物標誌物市場：按應用

  • 概覽
    • 市場規模和預測
  • 阿爾茨海默氏癡呆症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 多發性硬化症
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 帕金森病
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章神經生物標誌物市場：按地區

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機會
    • 北美市場規模和預測：按類型
    • 北美市場規模和預測：按應用
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
  • 歐洲
    • 主要趨勢和機會
    • 歐洲市場規模和預測：按類型
    • 歐洲市場規模和預測：按應用分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機會
    • 亞太市場規模和預測：按類型
    • 亞太市場規模和預測：按應用
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 印度
      • 其他亞太地區
  • 拉美
    • 主要趨勢和機會
    • LAMEA 市場規模和預測：按類型
    • LAMEA 市場規模和預測：按應用分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 沙特阿拉伯
      • LAMEA 的其餘部分

第七章商業條件

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 主要發展

第八章公司簡介

  • F. HOFFMANN-LA ROCHE LTD.
  • Bio-Rad Laboratories, Inc.
  • merck kgaa, darmstadt, germany
  • PERKINELMER INC.
  • shimadzu corporation
  • Thermo Fisher Scientific, Inc.
  • Quanterix
  • Neurobio
  • bioMerieux
  • MYRIAD RBM（MYRIAD GENETICS, INC.）
Product Code: A03215

Neurological biomarkers are measurable indicators of biological state or condition of patients suffering from neurodegenerative diseases. Brain diseases require plenty of markers to reflect the metabolic impairment of different brain cells. The recent introduction of the metabolomic approach helps the study of neurological diseases based on profiling a multitude of biochemical components related to brain metabolism.

Major factors driving growth of the neurological biomarkers market include increase in geriatric population that are prone to neurological diseases, rise in head injuries, rise in prevalence of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis. For instance, according to the latest WHO data published in 2020 Parkinson's disease deaths in Australia reached 2,036 or 1.49% of total deaths. The age adjusted Death Rate is 3.35 per 100,000 of population ranks Australia #131 in the world. According to WHO update 2022, globally, disability and death due to Parkinson's disease are increasing faster than for any other neurological disorder.

For instance, according to National Multiple Sclerosis Society 2019, between 750,000 and 1 million people in the U.S. over the age of 18 are living with MS. There are more people living with MS in the Northeast and Midwest than in the South. The rates of MS have increased worldwide since 1955. The first report of MS in the U.S. was published in 1976 and found 123,00 cases. A study from 1990 found 300,000 cases of MS. This compares to the estimated 750,000 to 1 million cases in 2019.

Moreover, neurology is one of the disciplines where personalized medicine has been emerging as an important part of treatment methods for Alzheimer's, Parkinson's and Multiple Sclerosis. Neurological biomarkers find a varied scope in personalized medicine, which eventually spurs the demand for diagnosis by incorporating neurological biomarkers. Therefore, rise in the demand for personalized medicine boost the growth of neurological biomarkers market.

Furthermore, increase in demand for minimally invasive procedures propels the adoption of neurological biomarkers product. In addition, technological advancements; launch of various products; strategies among key players such as acquisition, collaboration, and agreement drive the growth of the neurological biomarkers market. For instance, in June 2021, Genentech, a member of the Roche Group, and its parent company, Roche Holding AG, announced a partnership with University of California, San Francisco (UCSF) and UC Berkeley to speed up the development of new therapeutics for debilitating brain diseases and disorders of the central nervous system (CNS) such as Alzheimer's, Parkinson's, Huntington's, Amyotrophic lateral sclerosis (ALS) and autism. UCSF and UC Berkeley had received up to $53 million from Genentech over the course of the 10-year collaboration.

However, the emerging ethical issues regarding early diagnosis of Alzheimer's disease, Parkinson's disease, and multiple Sclerosis is expected to impede the market growth. strict government regulations and high cost for neurological biomarkers products also restrain the market growth.

Furthermore, healthcare business is predicted to witness growth, owing increase in focus on developing cost-effective biomarker testing increase in patient population, and rise in demand for non-invasive diagnostic techniques for Alzheimer's and Parkinson's, increase in R&D investments in drug discovery & development, and rise in awareness regarding neurological biomarker. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The neurological biomarkers market is segmented on the basis of type, application, and region. On the basis of type, the market is classified into genomic, proteomic, metabolomic, and others. By application, the market is segregated into Alzheimer's disease, Parkinson's disease, and multiple sclerosis. 

Region wise, the market is analyzed across North America (the U.S., and Canada), Europe (Germany, France, the UK, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and Rest of LAMEA).

Major players profiled in the report are Biomerieux, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Merck KGAA, Myriad Genetics, Inc., Neurobio, Perkinelmer Inc., Quanterix, Shimadzu Corporation, Thermo Fisher Scientific, Inc.

KEY BENEFITS FOR STAKEHOLDERS

  • This report provides an extensive analysis of the current and emerging market trends and dynamics in the diabetic nephropathy market to identify the prevailing opportunities
  • This study presents the competitive landscape of the global market to predict the competitive environment across various regions
  • Comprehensive analysis of factors that drive and restrict the market growth is provided
  • Region & country wise analysis is provided to understand the market trends and dynamics

Key Market Segments

By Type

  • Genomic
  • Proteomic
  • Metabolomic
  • Others

By Application

  • Parkinson's Disease
  • Alzheimer's Disease
  • Multiple Sclerosis

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • Rest Of LAMEA
  • Key Market Players
    • F. HOFFMANN-LA ROCHE LTD.
    • Bio-Rad Laboratories, Inc.
    • merck kgaa, darmstadt, germany
    • PERKINELMER INC.
    • shimadzu corporation
    • Thermo Fisher Scientific, Inc.
    • Quanterix
    • Neurobio
    • bioMerieux
    • MYRIAD RBM (MYRIAD GENETICS, INC.)

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: NEUROLOGICAL BIOMARKERS MARKET, BY TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Genomic
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Proteomic
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Metabolomic
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Alzheimer's Disease
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Multiple Sclerosis
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 Parkinson's Disease
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: NEUROLOGICAL BIOMARKERS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Type
    • 6.2.3 North America Market size and forecast, by Application
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Type
      • 6.2.4.1.2 Market size and forecast, by Application
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Type
      • 6.2.4.2.2 Market size and forecast, by Application
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Type
    • 6.3.3 Europe Market size and forecast, by Application
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Type
      • 6.3.4.1.2 Market size and forecast, by Application
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Type
      • 6.3.4.2.2 Market size and forecast, by Application
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Type
      • 6.3.4.3.2 Market size and forecast, by Application
      • 6.3.4.4 Rest of Europe
      • 6.3.4.4.1 Market size and forecast, by Type
      • 6.3.4.4.2 Market size and forecast, by Application
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Type
    • 6.4.3 Asia-Pacific Market size and forecast, by Application
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 Japan
      • 6.4.4.1.1 Market size and forecast, by Type
      • 6.4.4.1.2 Market size and forecast, by Application
      • 6.4.4.2 China
      • 6.4.4.2.1 Market size and forecast, by Type
      • 6.4.4.2.2 Market size and forecast, by Application
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Type
      • 6.4.4.3.2 Market size and forecast, by Application
      • 6.4.4.4 Rest of Asia-Pacific
      • 6.4.4.4.1 Market size and forecast, by Type
      • 6.4.4.4.2 Market size and forecast, by Application
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Type
    • 6.5.3 LAMEA Market size and forecast, by Application
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Type
      • 6.5.4.1.2 Market size and forecast, by Application
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Type
      • 6.5.4.2.2 Market size and forecast, by Application
      • 6.5.4.3 Rest of LAMEA
      • 6.5.4.3.1 Market size and forecast, by Type
      • 6.5.4.3.2 Market size and forecast, by Application

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 F. HOFFMANN-LA ROCHE LTD.
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories, Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 merck kgaa, darmstadt, germany
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 PERKINELMER INC.
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 shimadzu corporation
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 Thermo Fisher Scientific, Inc.
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Quanterix
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Neurobio
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 bioMerieux
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 MYRIAD RBM (MYRIAD GENETICS, INC.)
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 2. NEUROLOGICAL BIOMARKERS MARKET, FOR GENOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. NEUROLOGICAL BIOMARKERS MARKET FOR GENOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. NEUROLOGICAL BIOMARKERS MARKET, FOR PROTEOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 5. NEUROLOGICAL BIOMARKERS MARKET FOR PROTEOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 6. NEUROLOGICAL BIOMARKERS MARKET, FOR METABOLOMIC, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. NEUROLOGICAL BIOMARKERS MARKET FOR METABOLOMIC, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 8. NEUROLOGICAL BIOMARKERS MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 9. NEUROLOGICAL BIOMARKERS MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 11. NEUROLOGICAL BIOMARKERS MARKET, FOR ALZHEIMER'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. NEUROLOGICAL BIOMARKERS MARKET FOR ALZHEIMER'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 13. NEUROLOGICAL BIOMARKERS MARKET, FOR MULTIPLE SCLEROSIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. NEUROLOGICAL BIOMARKERS MARKET FOR MULTIPLE SCLEROSIS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 15. NEUROLOGICAL BIOMARKERS MARKET, FOR PARKINSON'S DISEASE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 16. NEUROLOGICAL BIOMARKERS MARKET FOR PARKINSON'S DISEASE, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 17. NEUROLOGICAL BIOMARKERS MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 19. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 20. NORTH AMERICA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 22. U.S. NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 23. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 24. CANADA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 25. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 26. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 27. EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 28. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 29. GERMANY NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 30. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. FRANCE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 32. UK NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 33. UK NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 34. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 35. REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 36. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 38. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 39. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 40. JAPAN NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 41. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 42. CHINA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 43. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 44. INDIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 45. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 46. REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 47. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 49. LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 50. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. BRAZIL NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 52. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 53. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 54. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 55. REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET, BY APPLICATION, 2021-2031 ($MILLION)
  • TABLE 56.F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 57.F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 58.F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 59.F. HOFFMANN-LA ROCHE LTD.: NET SALES,
  • TABLE 60.F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 61.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
  • TABLE 62.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
  • TABLE 63.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
  • TABLE 64.BIO-RAD LABORATORIES, INC.: NET SALES,
  • TABLE 65.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
  • TABLE 66.MERCK KGAA, DARMSTADT, GERMANY: COMPANY SNAPSHOT
  • TABLE 67.MERCK KGAA, DARMSTADT, GERMANY: OPERATING SEGMENTS
  • TABLE 68.MERCK KGAA, DARMSTADT, GERMANY: PRODUCT PORTFOLIO
  • TABLE 69.MERCK KGAA, DARMSTADT, GERMANY: NET SALES,
  • TABLE 70.MERCK KGAA, DARMSTADT, GERMANY: KEY STRATERGIES
  • TABLE 71.PERKINELMER INC.: COMPANY SNAPSHOT
  • TABLE 72.PERKINELMER INC.: OPERATING SEGMENTS
  • TABLE 73.PERKINELMER INC.: PRODUCT PORTFOLIO
  • TABLE 74.PERKINELMER INC.: NET SALES,
  • TABLE 75.PERKINELMER INC.: KEY STRATERGIES
  • TABLE 76.SHIMADZU CORPORATION: COMPANY SNAPSHOT
  • TABLE 77.SHIMADZU CORPORATION: OPERATING SEGMENTS
  • TABLE 78.SHIMADZU CORPORATION: PRODUCT PORTFOLIO
  • TABLE 79.SHIMADZU CORPORATION: NET SALES,
  • TABLE 80.SHIMADZU CORPORATION: KEY STRATERGIES
  • TABLE 81.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 82.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
  • TABLE 83.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
  • TABLE 84.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
  • TABLE 85.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
  • TABLE 86.QUANTERIX: COMPANY SNAPSHOT
  • TABLE 87.QUANTERIX: OPERATING SEGMENTS
  • TABLE 88.QUANTERIX: PRODUCT PORTFOLIO
  • TABLE 89.QUANTERIX: NET SALES,
  • TABLE 90.QUANTERIX: KEY STRATERGIES
  • TABLE 91.NEUROBIO: COMPANY SNAPSHOT
  • TABLE 92.NEUROBIO: OPERATING SEGMENTS
  • TABLE 93.NEUROBIO: PRODUCT PORTFOLIO
  • TABLE 94.NEUROBIO: NET SALES,
  • TABLE 95.NEUROBIO: KEY STRATERGIES
  • TABLE 96.BIOMERIEUX: COMPANY SNAPSHOT
  • TABLE 97.BIOMERIEUX: OPERATING SEGMENTS
  • TABLE 98.BIOMERIEUX: PRODUCT PORTFOLIO
  • TABLE 99.BIOMERIEUX: NET SALES,
  • TABLE 100.BIOMERIEUX: KEY STRATERGIES
  • TABLE 101.MYRIAD RBM (MYRIAD GENETICS, INC.): COMPANY SNAPSHOT
  • TABLE 102.MYRIAD RBM (MYRIAD GENETICS, INC.): OPERATING SEGMENTS
  • TABLE 103.MYRIAD RBM (MYRIAD GENETICS, INC.): PRODUCT PORTFOLIO
  • TABLE 104.MYRIAD RBM (MYRIAD GENETICS, INC.): NET SALES,
  • TABLE 105.MYRIAD RBM (MYRIAD GENETICS, INC.): KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION
  • FIGURE 2.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
  • FIGURE 3.NEUROLOGICAL BIOMARKERS MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.NEUROLOGICAL BIOMARKERS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.NEUROLOGICAL BIOMARKERS MARKET,BY TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF GENOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF PROTEOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF METABOLOMIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 17.NEUROLOGICAL BIOMARKERS MARKET,BY APPLICATION,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ALZHEIMER'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF MULTIPLE SCLEROSIS NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF PARKINSON'S DISEASE NEUROLOGICAL BIOMARKERS MARKET,2021-2031(%)
  • FIGURE 21.NEUROLOGICAL BIOMARKERS MARKET BY REGION,2021
  • FIGURE 22.U.S. NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 23.CANADA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 24.GERMANY NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 25.FRANCE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 26.UK NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 27.REST OF EUROPE NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 28.JAPAN NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 29.CHINA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 30.INDIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 31.REST OF ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 32.BRAZIL NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 33.SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 34.REST OF LAMEA NEUROLOGICAL BIOMARKERS MARKET,2021-2031($MILLION)
  • FIGURE 35. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 36. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 37. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 38.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 39.COMPETITIVE DASHBOARD
  • FIGURE 40.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 41.F. HOFFMANN-LA ROCHE LTD..: NET SALES ,($MILLION)
  • FIGURE 42.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
  • FIGURE 43.MERCK KGAA, DARMSTADT, GERMANY.: NET SALES ,($MILLION)
  • FIGURE 44.PERKINELMER INC..: NET SALES ,($MILLION)
  • FIGURE 45.SHIMADZU CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 46.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
  • FIGURE 47.QUANTERIX.: NET SALES ,($MILLION)
  • FIGURE 48.NEUROBIO.: NET SALES ,($MILLION)
  • FIGURE 49.BIOMERIEUX.: NET SALES ,($MILLION)
  • FIGURE 50.MYRIAD RBM (MYRIAD GENETICS, INC.).: NET SALES ,($MILLION)